Ventana HPV (Human Papilloma Virus) episode adds new chapter to US "home brew" debate
This article was originally published in Clinica
In the latest twist in its slowly-evolving policy regarding "home-brew" tests, the US FDA has informed Ventana Medical Systems of Tucson, Arizona, that it cannot market its automated slide-based staining system for the detection of the human papillomavirus without going through the agency's premarket approval process.
You may also be interested in...
Royal Philips is planning to sell its domestic appliance business to better focus on its strategic aims in health technology. The group made the announcement as it unveiled 2019 sales up 4.5% on a comparable basis.
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
Denmark is moving to a QALY based evaluation system for hospital drugs. Despite a more complex process, the change could still mean quicker market access, says the pharmaceutical industry.